Skip to main content

Table 1 Approved indications and pharmacokinetic properties of vancomycin, linezolid, tigecycline and daptomycin [4, 25, 46, 70]

From: Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin

  Vancomycin Linezolid Tigecycline Daptomycin
Approved Indications (FDA) Serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. Vancomycin-Resistant E. faecium infections Complicated skin and skin structure infections. Complicated skin and skin structure infections.
  Alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis. Nosocomial pneumonia caused by S. aureus or S. pneumoniae including multi-drug resistant strains Complicated intra-abdominal infections. S. aureus Bloodstream Infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.
  For endocarditis caused by enterococci (e.g., E. faecalis) only in combination with an aminoglycoside. Complicated skin and skin structure infections, including diabetic foot infections Community-acquired bacterial pneumonia  
   Uncomplicated skin and skin structure infections caused by MSSA or S. pyogenes.   
   Community-acquired pneumonia caused by MSSA   
Oral Bioavailability Not absorbed Not absorbed Not absorbed Completely absorbed
Clearance 0.06 L/h/kg 0.01 L/h/kg 0.33 L/h/kg 0.10 L/h/kg
Volume of Distribution 0.3 to 0.43 L/kg 0.1 L/kg 8-9 L/kg 0.7-0.8 L/kg
Half-Life 4-6 h 8 h 27-42 h 4-5 h
Protein Binding 55% 90-93% 71-89% 31%
Major Route of renal renal biliary metabolism
Elimination     30% renal
Tissue Penetration moderate low very high high
Usual Dosing Regimen 1000 mg IV over 60 min.
Q12h with Drug Level Monitoring
4-6 mg/kg IV over 30 min.
Q24h
50 mg IV over 30-60 min.
Q 12h First dose 100 mg IV
600 mg IV over 30-120 min.
Q12h 400-600 mg PO Q12h
Dosing in Renal Impairment Increased Dosing Interval with Drug Level Monitoring Increased Dosing Interval No dose adjustment No dose adjustment